A common anti-sickness drug carries a risk of involuntary movement disorders

A common anti-sickness drug carries a risk of involuntary movement disorders
Image: Intellect (generated)

In short: Metoclopramide is a widely prescribed medicine for nausea and vomiting. Its most notable risk is involuntary movement, and regulators have limited how long it should be taken. The evidence explains who should be cautious and why short courses matter.

Metoclopramide is an anti-sickness medicine used to prevent or treat nausea and vomiting, including sickness after chemotherapy or radiotherapy and the sickness that can accompany a migraine. It usually comes as tablets or a liquid and is normally prescribed for a short period. Patients are advised to leave at least six hours between doses and never to double up to make up for a missed one. The packaging and official guidance both warn that it can produce unwanted effects when taken for longer than five days. The most important concern is movement. The most common serious side effect is involuntary motion, including tics, tremors and muscle stiffness, which can appear soon after starting treatment and may indicate that the dose needs adjusting.

A specialist review describes metoclopramide as possibly the most frequent cause of drug-induced movement disorders. The risk is greater in people under 20 and with high or prolonged dosing. Tardive dyskinesia, a movement disorder, may persist in some people, and most reported cases occur after more than three months of use. In response, the US Food and Drug Administration recommends short-term use, preferably under 12 weeks, and in 2009 required a boxed warning about chronic or high-dose use. European regulators reviewed the drug in 2011 and advised against high doses, courses longer than five days, and use in infants under one year. Other serious effects reported include severe allergic reactions, neuroleptic malignant syndrome, hallucinations and a slowed heartbeat.

Evidence on pregnancy is more reassuring. Large cohort studies, including one of Israeli births and one in Denmark, found no clear association with birth defects, low birth weight, early delivery or miscarriage, and clinicians weigh benefits against risks case by case. A newer systematic review and network meta-analysis of 17 studies, involving 2,654 critically ill patients, ranked a combination with erythromycin as most effective for achieving feeding success. The authors caution that the trials were small and that their certainty is only moderate. Metoclopramide alone had a more favourable safety profile than the combination.

Read the leaflet before use, tell a pharmacist or doctor about any side effects that persist, and avoid driving while drowsy.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/health-metoclopramide.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…